Cargando…

The Combination Treatment of Fosmanogepix and Liposomal Amphotericin B Is Superior to Monotherapy in Treating Experimental Invasive Mold Infections

Invasive pulmonary aspergillosis (IPA), invasive mucormycosis (IM), and invasive fusariosis (IF) are associated with high mortality and morbidity. Fosmanogepix (FMGX) is a first-in-class antifungal in clinical development with demonstrated broad-spectrum activity in animal models of infections. We s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gebremariam, Teclegiorgis, Gu, Yiyou, Alkhazraji, Sondus, Youssef, Eman, Shaw, Karen Joy, Ibrahim, Ashraf S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Microbiology 2022
Materias:	Experimental Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9295579/ https://www.ncbi.nlm.nih.gov/pubmed/35670592 http://dx.doi.org/10.1128/aac.00380-22

Ejemplares similares

Galactomannan Is a Biomarker of Fosmanogepix (APX001) Efficacy in Treating Experimental Invasive Pulmonary Aspergillosis
por: Gebremariam, Teclegiorgis, et al.
Publicado: (2019)

Fosmanogepix (APX001) Is Effective in the Treatment of Immunocompromised Mice Infected with Invasive Pulmonary Scedosporiosis or Disseminated Fusariosis
por: Alkhazraji, Sondus, et al.
Publicado: (2020)

Fosmanogepix (APX001) Is Effective in the Treatment of Pulmonary Murine Mucormycosis Due to Rhizopus arrhizus
por: Gebremariam, Teclegiorgis, et al.
Publicado: (2020)

726. APX001 (Fosmanogepix) Is Effective in an Immunosuppressed Mouse Model of Rhizopus oryzae Infection
por: Gebremariam, Teklegiorgis, et al.
Publicado: (2019)

LB1580. Efficacy Assessment of MAT2203 Encochleated Oral Formulation of Amphotericin B, in the Neutropenic Mouse Model of Pulmonary Mucormycosis
por: Gebremariam, Teclegiorgis, et al.
Publicado: (2022)

678. Galactomannan Is a Biomarker of APX001 (Fosmanogepix) Efficacy in Treating Experimental Invasive Pulmonary Aspergillosis
por: Gebremariam, Teklegiorgis, et al.
Publicado: (2019)

APX001 Is Effective in the Treatment of Murine Invasive Pulmonary Aspergillosis
por: Gebremariam, Teclegiorgis, et al.
Publicado: (2019)

745. Combination Treatment of Liposomal Amphotericin B and Isavuconazole is Synergistic in Treating Experimental Mucormycosis
por: Gebremariam, Teclegiorgis, et al.
Publicado: (2020)

Combination treatment of liposomal amphotericin B and isavuconazole is synergistic in treating experimental mucormycosis
por: Gebremariam, Teclegiorgis, et al.
Publicado: (2021)

119. A Humanized Antibody Targeting the CotH Invasins is Protective Against Murine Mucormycosis
por: Gu, Yiyou, et al.
Publicado: (2021)

1705. Filamentous Hemagglutinin Polyclonal Antibodies Protect against Multidrug resistant Gram-negative bacteria
por: Youssef, Eman, et al.
Publicado: (2022)

APX001A Protects Immunosuppressed Mice from Rhizopus delemar Infection
por: Gebremariam, Teclegiorgis, et al.
Publicado: (2017)

969. GRP78 and Integrin β1/α3 Play Disparate Roles in Epithelium Invasion During Mucormycosis
por: Alqarihi, Abdullah, et al.
Publicado: (2018)

Monoclonal IgM Antibodies Targeting Candida albicans Hyr1 Provide Cross-Kingdom Protection Against Gram-Negative Bacteria
por: Youssef, Eman G., et al.
Publicado: (2020)

GRP78 and Integrins Play Different Roles in Host Cell Invasion during Mucormycosis
por: Alqarihi, Abdullah, et al.
Publicado: (2020)

2393. Evaluation of Antifungal Treatment in a Neutropenic Mouse Model of Scedosporiosis
por: Alkhazraji, Sondus, et al.
Publicado: (2018)

PCR-based Diagnosis of Mucormycosis Targeting Mucorales-specific Genes
por: Baldin, Clara, et al.
Publicado: (2017)

Safety and Pharmacokinetics of Intravenous and Oral Fosmanogepix, a First-in-Class Antifungal Agent, in Healthy Volunteers
por: Hodges, Michael R., et al.
Publicado: (2023)

Efficacy of Delayed Therapy with Fosmanogepix (APX001) in a Murine Model of Candida auris Invasive Candidiasis
por: Wiederhold, Nathan P., et al.
Publicado: (2019)

Fosmanogepix: A Review of the First-in-Class Broad Spectrum Agent for the Treatment of Invasive Fungal Infections
por: Shaw, Karen Joy, et al.
Publicado: (2020)

Anti-CotH3 antibodies protect mice from mucormycosis by prevention of invasion and augmenting opsonophagocytosis
por: Gebremariam, Teclegiorgis, et al.
Publicado: (2019)

Evaluation of Sex Differences in Murine Diabetic Ketoacidosis and Neutropenic Models of Invasive Mucormycosis
por: Gebremariam, Teclegiorgis, et al.
Publicado: (2021)

Clinical Efficacy and Safety of a Novel Antifungal, Fosmanogepix, in Patients with Candidemia Caused by Candida auris: Results from a Phase 2 Trial
por: Vazquez, Jose A., et al.
Publicado: (2023)

Mucoricin is a Ricin-Like Toxin that is Critical for the Pathogenesis of Mucormycosis
por: Soliman, Sameh S. M., et al.
Publicado: (2021)

97. A Cross-kingdom Vaccine Protects against Multiple Healthcare-associated Infections
por: Singh, Shakti, et al.
Publicado: (2022)

Protective Efficacy of Anti-Hyr1p Monoclonal Antibody against Systemic Candidiasis Due to Multi-Drug-Resistant Candida auris
por: Singh, Shakti, et al.
Publicado: (2023)

Economic impact of treating invasive mold disease with isavuconazole compared with liposomal amphotericin B in the UK
por: Bagshaw, Emma, et al.
Publicado: (2018)

Inhibition of EGFR Signaling Protects from Mucormycosis
por: Watkins, Tonya N., et al.
Publicado: (2018)

Liposomal amphotericin B—the present
por: Maertens, J, et al.
Publicado: (2022)

Liposomal amphotericin B—the past
por: Brüggemann, R J, et al.
Publicado: (2022)

Liposomal amphotericin B—the future
por: Hoenigl, M, et al.
Publicado: (2022)

The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin
por: Hoenigl, Martin, et al.
Publicado: (2021)

Liposomal Amphotericin B Treatment and the Leishmaniases
por: Berman, Jonathan
Publicado: (2019)

Toxicity of Amphotericin B Deoxycholate-Based Induction Therapy in Patients with HIV-Associated Cryptococcal Meningitis
por: Bicanic, Tihana, et al.
Publicado: (2015)

Olmesartan‐based monotherapy vs combination therapy in hypertension: A meta‐analysis based on age and chronic kidney disease status
por: Deedwania, Prakash, et al.
Publicado: (2017)

Amphotericin-B/amphotericin-B-liposomal: Lack of efficacy: 2 case reports
Publicado: (2022)

Phase I EnACT Trial of the Safety and Tolerability of a Novel Oral Formulation of Amphotericin B
por: Skipper, Caleb P., et al.
Publicado: (2020)

Liposomal Amphotericin B and Leishmaniasis: Dose and Response
por: Sundar, Shyam, et al.
Publicado: (2010)

Amphotericin-B-liposomal: No improvement: case report
Publicado: (2022)

Amphotericin-B-liposomal: Anaphylaxis: case report
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_3ei1u81k1si5hv13m6s66pkq4t